B

Biome Australia Ltd
ASX:BIO

Watchlist Manager
Biome Australia Ltd
ASX:BIO
Watchlist
Price: 0.535 AUD -1.83% Market Closed
Market Cap: 117.2m AUD
Have any thoughts about
Biome Australia Ltd?
Write Note

Biome Australia Ltd
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biome Australia Ltd
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
B
Biome Australia Ltd
ASX:BIO
Current Portion of Long-Term Debt
AU$2.5m
CAGR 3-Years
445%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bioxyne Ltd
ASX:BXN
Current Portion of Long-Term Debt
AU$183k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
McPherson's Ltd
ASX:MCP
Current Portion of Long-Term Debt
AU$14.1m
CAGR 3-Years
48%
CAGR 5-Years
53%
CAGR 10-Years
18%
Star Combo Pharma Ltd
ASX:S66
Current Portion of Long-Term Debt
AU$156.6k
CAGR 3-Years
-4%
CAGR 5-Years
73%
CAGR 10-Years
N/A
Elixinol Wellness Ltd
ASX:EXL
Current Portion of Long-Term Debt
AU$545k
CAGR 3-Years
-16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hydration Pharmaceuticals Co Ltd
ASX:HPC
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Biome Australia Ltd
Glance View

Market Cap
115.1m AUD
Industry
Consumer products

Biome Australia Ltd. engages in the development and marketing of live biotherapeutics and complementary medicines. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-30. The firm licenses, develops and markets evidence-based, complementary medicines, including nutraceuticals (food-based vitamins and weight management products) and live biotherapeutics (probiotics). The company markets and distributes clinically researched products developed in conjunction with its strategic partners. Its products include 22 products marketed under three brands, being Activated Probiotics, Activated Nutrients and Activated X Performance. These products are distributed through community pharmacies, independent health practitioners and online direct to consumer channels. The company offers biotherapeutic products to help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and irritable bowel syndrome (IBS), through randomized double-blind placebo-controlled trials.

BIO Intrinsic Value
0.34 AUD
Overvaluation 36%
Intrinsic Value
Price
B

See Also

What is Biome Australia Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
2.5m AUD

Based on the financial report for Jun 30, 2024, Biome Australia Ltd's Current Portion of Long-Term Debt amounts to 2.5m AUD.

What is Biome Australia Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 3Y
445%

Over the last year, the Current Portion of Long-Term Debt growth was 1 032%. The average annual Current Portion of Long-Term Debt growth rates for Biome Australia Ltd have been 445% over the past three years .

Back to Top